A review of the published literature, supplemented with a recent analysis of Fred Hutchinson data, has been undertaken to investigate the association of infused CD34 cell dose with various clinical outcomes after HLAidentical transplantation. Separate assessments for unrelated vs related donors and the use of bone marrow or mobilized G-PBMC have been incorporated. The three primary findings are: (1) higher CD34 dose results in better neutrophil and platelet recovery in all settings; (2) high CD34 doses (48 Â 10 6 /kg) are associated with the development of more chronic GVHD when using related G-PBMC; (3) higher CD34 dose is correlated with improved survival after bone marrow transplantation, especially with unrelated donors. This is not seen when using G-PBMC. The data suggest that the CD34 content of the graft can have a significant impact on clinical outcome after allogeneic transplantation, but optimal dose is dependent on both donor type and stem cell source.
plantation; GVHD; survival; unrelated donor Allogeneic transplantation of bone marrow (BM), G-CSFmobilized peripheral blood mononuclear cells (G-PBMC), or umbilical cord blood (UCB) is increasingly being utilized to treat a wide variety of malignant and nonmalignant diseases as well as certain congenital disorders. Clinical outcomes after such therapy, such as overall survival or graft-versus-host disease (GVHD), depend on many patient and disease specific factors, along with the degree of HLA matching between the donor and the recipient. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] In addition, it appears that some of these clinical outcomes can also be influenced by the source of stem cells used for the transplant, the number of total cells in the graft, and the doses of different cellular subpopulations within the graft. [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] CD34 designates a cell-surface antigen whose expression is generally restricted to the primitive stem/ progenitor cell compartment of the hematopoietic system. As such, it has been widely used as a surrogate quantitative marker for stem cell content in BM, G-PBMC, and UCB. In this report, recent published literature on the association of this one specific graft parameter, the infused dose of CD34 + cells, with various clinical outcomes after allogeneic BM or G-PBMC transplantation has been reviewed. [22] [23] [24] [25] [26] [27] [28] [29] [30] Data on the association of cell dose with outcome after UCB transplantation have been recently published, [31] [32] [33] and will not be covered in this paper. Also not included in this review are allogeneic transplants involving manipulated components (eg CD34 enrichment or T-cell depletion) or nonmyeloablative conditioning regimens. [34] [35] [36] [37] The relation between CD34 cell dose and clinical outcomes is likely to be different in those settings. In a few cases, supplemental results from recent analyses done with the Fred Hutchinson Cancer Research Center's (FHCRC) large database of matched related and matched unrelated donors have been incorporated into this review to illustrate specific points. The specific questions that are addressed are whether outcomes such as engraftment, GVHD, and survival can be correlated with the number of CD34 + cells infused into the recipient, and whether minimum and/or maximum target cell doses can be defined for optimal clinical benefit.
Important considerations in these types of analyses are other variables such as the type of donor, related vs unrelated, and the source of CD34 + cells, BM vs G-PBMC (see Table 1 ). These factors have clearly been shown to have an influence on clinical outcomes, and thus an analysis of CD34 + cell dosage effects must take these other variables into account. Similarly, different clinical end points such as engraftment, GVHD, or survival should also be analyzed separately, as there is no a priori reason that particular CD34 + cell doses will yield identical target values in each of these various clinical settings and outcomes. Finally, statistical methods must be employed to ensure that other patient parameters (eg age, type of disease) that can also affect these clinical outcomes are accounted for in these correlative studies. That is the approach generally taken in this review, correlations of CD34 + cell dose with clinical outcomes have been analyzed separately for related BM, unrelated BM, related G-PBMC, and unrelated G-PBMC.
Flow cytometry analysis for CD34 content
Before beginning this review, it is important to acknowledge some technical concerns regarding the enumeration of CD34 + cells. Quantitative flow cytometry has become the preferred method to determine the number of CD34 + cells in a BM or G-PBMC graft. There are a variety of different techniques that are employed among clinical laboratories, including the ISHAGE, Milan, and Norway protocols, along with commercial reagents such as ProCOUNTt from Becton Dickinson and Stem Kitt from Beckman Coulter, for quantitative CD34 assessment. [38] [39] [40] [41] [42] [43] [44] Each of these methods utilizes slightly different staining combinations and/or gating strategies that can result in somewhat different final values. It is important to keep in mind that when a specific cell dose is referred to in the published literature, it may not correspond exactly to the same dose that would be determined by another clinical site using a different procedure. Thus, when reviewing CD34 dose-response relations, the actual flow cytometry technique used must be acknowledged as that may have an influence on the reported values. At the FHCRC, we routinely use a three-color combination of CD34-PE/ CD14-FITC/7-AAD staining, collecting a minimum of 100 000 events (
45
: an example of G-PBMC staining is shown in Figure 1 ). That sample was first gated on total nucleated cells (Region R1: Figure 1a) , followed by exclusion of nonviable 7-AAD + cells (not shown), followed by exclusion of CD14 + high-side scatter populations (Region R2: Figure 1b ; previous work has shown that no normal CD34 + cells are also CD14 + ). Specific gating on the brightest expressing CD34 + cell population (Region R3: Figure 1c ) is then used to determine the total number of CD34 + events. This number is divided by the R1 events to obtain the percentage of viable CD34 + cells, and then multiplied by the total nucleated cells in the graft to determine the total number of CD34 + cells infused in that component. When multiple components are harvested (eg in certain G-PBMC protocols), all infused components are summed to give the total dose of CD34 + cells/kg of actual patient body weight that was given for the transplant.
Characteristics of FHCRC database for allogeneic components
The FHCRC has developed an extensive database over the last few years in which CD34 dosage information within the allogeneic BM or G-PBMC grafts has been determined.
Some of the summary characteristics of that database are listed in Table 2 + cells differ on average by approximately three-fold, which could have a potential impact when comparing clinical outcomes. Also important to note are the greater than one log differences in the ranges within the subgroups, with s.d.'s that are similar in size to the median values. It is this wide variation in infused CD34
+ cell doses that serves as the basis for the correlative studies described below.
Association of CD34 dose with neutrophil and platelet engraftment
Numerous publications have reported that higher doses of CD34 + cells are associated with more rapid recovery of neutrophils after allogeneic transplantation, using either BM or G-PBMC as the source of cells. 8, 10, [12] [13] [14] [22] [23] [24] [25] [26] [27] [28] [29] [30] Within the related G-PBMC subgroup, days to recovery of absolute neutrophil counts (ANC) greater than 500/ml plotted against infused CD34 + cell dose does show a correlation, a higher dose resulting in slightly shorter median times to engraftment. 29 However, it is clear from these studies that there is no strict dose-response relation. Most studies report only a 1-2 day median difference in terms of ANC recovery between lower and higher CD34 doses. It should also be acknowledged that one reason for these small differences could be an artefact of the various clinical trial designs. For example, nearly all FHCRC allogeneic G-PBMC protocols have required a minimum cell dose of 44 Â 10 6 CD34 + cells/kg. If this is not obtained in one collection, additional aphereses are performed until the minimum dose is achieved (up to a maximum of four collections). Thus, there are relatively few patients below the level of 4 Â 10 6 CD34 + cells/kg, and that level may be above any threshold value where more significant delays in ANC recovery might be seen.
In randomized studies comparing BM vs G-PBMC, there is a significant difference in neutrophil recovery times, with G-PBMC generally showing 5-7 days faster recovery times.
12-14 While this may not be surprising given the median three-fold higher content of CD34 + cells in G-PBMC (Table 2) , this difference holds true even when comparing similar doses of CD34 cells from BM and G-PBMC. Thus, faster ANC recovery is not just a function of the quantity of CD34 cells, but likely also reflects qualitative differences in the CD34 cells from those sources. 46 It is also possible that other cell types besides the CD34 + cells found in G-PBMC grafts may contribute to this faster recovery, although similar differences in ANC recovery between BM and G-PBMC can be obtained using purified CD34 cells for transplantation. 35 The story with respect to platelet engraftment is very similar. Again there is a statistically significant association with higher CD34 doses yielding faster recovery times, with G-PBMC showing 5-12 days faster engraftment than BM. [22] [23] [24] [25] [26] [27] [28] [29] [30] Publications have suggested that a subset of the total CD34 + cells, CD41 + or CD42 + , may be an even better predictor of platelet recovery. 47 Another way of looking at engraftment is to analyze the proportion of patients who do not recover their counts within a specified time. With related G-PBMC at lower CD34 doses (o4 Â 10 6 /kg actual patient body weight), 10% of the patients do not recover their platelet counts within 30 days after transplantation, whereas at higher dose ranges (410 Â 10 6 /kg), all patients recover their counts above 20 000 by day 20. 29 A similar effect is seen with slightly different kinetics for related BM, where, in this case, patients with the lowest doses (o2 Â 10 6 /kg) show a longer time for platelet engraftment and a much higher proportion of patients do not recover their platelet counts to 20 000 before day 30. 26 From this type of study, minimum threshold values of 42 Â 10 6 CD34 + cells/kg have been suggested for BM, with higher minimum values of 3-5 Â 10 6 CD34 + cells/kg being used for G-PBMC. Above these threshold values, increasing the CD34 dose does not generally result in significantly more rapid ANC or platelet recovery times.
Finally, several publications have indicated that total infused nucleated marrow cell dose also correlates with initial and secondary graft failure, with higher doses giving better outcomes. [15] [16] [17] 19, 20, [48] [49] [50] These published analyses have not directly addressed the issue of whether this effect is directly associated with the number of CD34 + cells in the graft, although that is likely to be the case.
Association of CD34 dose with GVHD

Acute GVHD
In general, the published literature indicates that there is little correlation between CD34 cell dose and acute GVHD (aGVHD) in the related BM setting. 28, 30, [50] [51] [52] With unrelated BM, several reports have suggested an association between total nucleated marrow cell dose and aGVHD, with higher numbers giving a lower incidence of grade III-IV aGVHD. 17, 18, 20 These papers either did not measure or did not report on any possible correlation with CD34 + cells, and no biological explanation for this finding was given. In addition, other investigators, analyzing either total nucleated or CD34 + cells, have not found a similar association. 19, 27, 48, 49 For related G-PBMC, the report by Przepiorka et al 24 found an association between CD34 dose and aGVHD, while another publication from the FHCRC by Zaucha et al 29 did not find any such correlation. This may reflect significant differences in the GVHD prophylaxis used in these two studies. Further follow-up with more recent FHCRC data still shows no association of CD34 doses with aGVHD (unpublished results). Randomized trials comparing BM to G-PBMC have suggested similar rates of aGVHD, which given the higher CD34 doses in G-PBMC (Table 2 ) again might suggest that CD34 dose by itself will not correlate with aGVHD. However, it is clear that additional data needs to be analyzed to better address this point. To date, very little data has yet been presented using unrelated G-PBMC, so possible associations with CD34 + cell dose remain undefined.
Chronic GVHD
In the related BM setting, CD34 dose does not appear to correlate with chronic GVHD (cGVHD), and with unrelated G-PBMC there is not yet enough published data and long-term follow-up to make any definitive conclusions. With unrelated BM transplantation, there is a suggestion in some publications that higher CD34 doses do lead to decreases in cGVHD, 28, 49, 52 although other reports did not find any statistical significance. 17, 30 The best correlation of CD34 dose and cGVHD has been obtained with related G-PBMC. Przepiorka /kg vs all others, a significant increase in cGVHD from 40 to 450% is found. This association has been further characterized in the current FHCRC database, as shown in Figure 2 . Separating the range of CD34 dosages into 20% quintiles, the lower four quintiles show identical levels of cGVHD, while the fifth quintile (410 Â 10 6 /kg) again shows a significantly higher rate of cGVHD. The biological explanation for this finding is unclear. One possible hypothesis for increased levels of cGVHD may have to do with better reconstitution of donor dendritic cells and/or donor T-cells from the larger number of CD34 + cells within the graft.
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Association of CD34 dose with overall survival
In allogeneic transplants involving the use of related BM, a clear association between higher total nucleated and/or higher CD34 + cells and better survival has been seen. 19, 28, 30, 50, 51 In general, this improvement at higher cell doses reflects decreases in transplant-related mortality because of infections or secondary graft failures rather than reductions in other components such as the relapse rate. Most of these studies have simply divided the patient populations into those above or below the median cell doses (approximately 43 Â 10 8 TNC/kg or 43 Â 10 6 CD34 cells/kg), thus it remains unclear whether these values reflect true minimum or threshold cell doses above which there might be even further improvements in survival.
A very significant association of total nucleated or CD34 + cell dose with survival has also been found for unrelated BM transplants. 17, 26, 27, 48, 49 This is shown graphically in Figure 3 with an analysis of results taken from the FHCRC database. Again splitting CD34 dosages into quintiles, a clear dose-response relation was observed. The lowest 20% cell dose showed 40% survival at 2 years, the next quintile at 50%, and the other quintiles progressively better at 60-70%. A more extensive multivariate analysis of this data, adjusting for patient age and disease risk, indicates that the most significant predictor for overall mortality is the dose of CD34 + cells. This improvement in overall survival again seems to be driven by a reduction in nonrelapse mortality, that is, no difference in the relapse rates was seen between the patients getting the lower vs higher CD34 + cell doses. Although there are only a few publications to date, there appears to be minimal correlation between the dose of CD34 cells and overall survival in the case of allogeneic transplants using related G-PBMC. [12] [13] [14] 29 As stated earlier, it is still too early to tell what the situation will be with unrelated G-PBMC. However, in preliminary analyses with the FHCRC data, there is an intriguing suggestion of CD34 dose also affecting survival outcomes. Separating the dose of CD34 again into quintiles, the two lowest quintiles (o7 Â 10 6 /kg) show the worst outcomes with survival at 1 year of 30-40%. The third and the fourth quintiles (7-10 Â 10 6 /kg) do better, with 1 year survival at 60-70%. The fifth quintile (410 Â 10 6 /kg) starts out similar to the third and fourth, but then tends to drop off with time so that at 1 year survival was only 40% (Heimfeld, unpublished observations). This sort of effect may indicate that, in this specific case of the unrelated G-PBMC setting, an optimum CD34+ cell number may lie somewhere in the middle of the dose ranges. The lower CD34 + cell dosages are not optimal, perhaps because of poorer engraftment, while the highest CD34 doses are also not preferable, but this may be for a different reason such as increased cGVHD (see above). Additional data, further follow-up, and more detailed analyses will be required to better explore this finding.
One prospective randomized trial has shown that there is a survival advantage for matched related allogeneic transplant recipients who received G-PBMC vs those who received BM as a source of stem cells.
14 The biological basis for this advantage is not entirely clear. As noted above, G-PBMC have on average three-fold more CD34 + cells than BM. However, this is unlikely to be the whole explanation for the improvement in survival, in almost every other lineage such as T-cell subsets, monocytes, B cell and NK cells, the differences between BM and G-PBMC are even larger (10 to 30 fold). The association of these other cell populations with clinical outcomes is just beginning to be investigated. 52 In addition, there are also qualitative differences in the cell populations in BM as compared with G-PBMC. G-CSF mobilization and apheresis collection does result in significant changes in gene expression within the CD34 compartment when compared with BM. 46 Other changes occur in dendritic cell subsets after G-CSF mobilization. 53 Further analyses will be necessary to examine the association of these other cell populations with clinical outcomes in each of these different clinical settings.
Summary
In this review, the dose-response relation of CD34 + cells with clinical outcomes such as engraftment, GVHD, and overall survival after HLA-matched allogeneic transplantation have been discussed. In all cases, higher CD34 + cell doses are associated with faster recovery of neutrophils and platelets, and reduce the incidence of initial and secondary rejections. Based on this engraftment data, there is a suggestion that CD34 doses of 42 Â 10 6 cells/kg should be considered minimum threshold values for BM, with higher doses of 44 Â 10 6 cells/kg for G-PBMC. With related BM, there is minimal association of CD34 + dose with either acute or chronic GVHD. However, with unrelated BM, a few publications suggest higher CD34 doses are associated with less acute or chronic GVHD, but this is not a consistent finding. For related G-PBMC, there appears to be no correlation of CD34 dose with aGVHD, but there is a clear association of the highest CD34 dosages (48-10 Â 10 6 cells/kg) with a greater frequency of extensive cGVHD (Figure 2 ). For unrelated G-PBMC, there is insufficient published data to draw any conclusions at this point. Finally, higher CD34 numbers are strongly correlated with improved survival in both the related and unrelated BM settings. The URD data, in particular, suggest a true dose-response relation ( Figure 3) . As far as related G-PBMC, there is no evidence that CD34 dose has any influence on overall survival. With unrelated G-PBMC, there is a suggestion that the lowest and highest CD34 dosages are associated with worse survival, but more data and more long-term follow-up are necessary before a definite conclusion can be made.
